Which has preferable earnings & valuation, DRMA or ZVSA?

Dermata Therapeutics is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dermata Therapeutics N/A N/A -$7.56M -$5.31 N/A ZyVersa Therapeutics N/A N/A -$9.41M -$0.83 N/A

Is DRMA or ZVSA more profitable?

ZyVersa Therapeutics' return on equity of -109.54% beat Dermata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dermata Therapeutics N/A -127.91% -105.05% ZyVersa Therapeutics N/A -109.54% -43.95%

Do analysts recommend ZVSA or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, ZVSA or ENVB?

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ZyVersa Therapeutics N/A N/A -$9.41M -$0.83 N/A Enveric Biosciences N/A N/A -$8.77M -$23.54 N/A

Is ZVSA or ENVB more profitable?

ZyVersa Therapeutics' return on equity of -109.54% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets ZyVersa Therapeutics N/A -109.54% -43.95% Enveric Biosciences N/A -220.97% -177.47%

Do analysts rate GOVX or ZVSA?

GeoVax Labs presently has a consensus price target of $150.00, indicating a potential upside of 12,505.04%. Given GeoVax Labs' stronger consensus rating and higher probable upside, research analysts clearly believe GeoVax Labs is more favorable than ZyVersa Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GOVX or ZVSA more profitable?

ZyVersa Therapeutics' return on equity of -109.54% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -709.52% -399.33% ZyVersa Therapeutics N/A -109.54% -43.95%

Do analysts rate RDHL or ZVSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is RDHL or ZVSA more profitable?

Redhill Biopharma's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A ZyVersa Therapeutics N/A -109.54% -43.95%

Do analysts recommend ZVSA or RNAZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, ZVSA or RNAZ?

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ZyVersa Therapeutics N/A N/A -$9.41M -$0.83 N/A TransCode Therapeutics N/A N/A -$34.66M -$50.33 N/A

Is ZVSA or RNAZ more profitable?

ZyVersa Therapeutics' return on equity of -109.54% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ZyVersa Therapeutics N/A -109.54% -43.95% TransCode Therapeutics N/A -875.35% -50.36%

ZyVersa Therapeutics (ZVSA) Competitors

$0.14 0.00 (0.00%)

As of 07/2/2026 02:29 PM Eastern

Compare

ZVSA vs. DRMA, ENVB, GOVX, RDHL, and RNAZ

Should you buy ZyVersa Therapeutics stock or one of its competitors? MarketBeat compares ZyVersa Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ZyVersa Therapeutics include Dermata Therapeutics (DRMA), Enveric Biosciences (ENVB), GeoVax Labs (GOVX), Redhill Biopharma (RDHL), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical products" industry.

How does ZyVersa Therapeutics compare to Dermata Therapeutics?

Dermata Therapeutics (NASDAQ:DRMA) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Dermata Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 646.27%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Dermata Therapeutics is more favorable than ZyVersa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ZyVersa Therapeutics' return on equity of -109.54% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-127.91%	-105.05%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

In the previous week, Dermata Therapeutics' average media sentiment score of 0.00 equaled ZyVersa Therapeutics'average media sentiment score.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
ZyVersa Therapeutics	Neutral

Dermata Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Dermata Therapeutics is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

Summary

Dermata Therapeutics beats ZyVersa Therapeutics on 6 of the 11 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Enveric Biosciences?

ZyVersa Therapeutics (NASDAQ:ZVSA) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

ZyVersa Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A

3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by insiders. Comparatively, 2.4% of Enveric Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, ZyVersa Therapeutics' average media sentiment score of 0.00 beat Enveric Biosciences' score of -0.35 indicating that ZyVersa Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
ZyVersa Therapeutics	Neutral
Enveric Biosciences	Neutral

ZyVersa Therapeutics' return on equity of -109.54% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZyVersa Therapeutics	N/A	-109.54%	-43.95%
Enveric Biosciences	N/A	-220.97%	-177.47%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Enveric Biosciences beats ZyVersa Therapeutics on 6 of the 10 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to GeoVax Labs?

GeoVax Labs (NASDAQ:GOVX) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

ZyVersa Therapeutics' return on equity of -109.54% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-709.52%	-399.33%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

GeoVax Labs has a beta of 3.68, indicating that its share price is 268% more volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

ZyVersa Therapeutics has lower revenue, but higher earnings than GeoVax Labs. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.66	-$21.47M	-$19.12	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

GeoVax Labs presently has a consensus price target of $150.00, indicating a potential upside of 12,505.04%. Given GeoVax Labs' stronger consensus rating and higher probable upside, research analysts clearly believe GeoVax Labs is more favorable than ZyVersa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, GeoVax Labs had 2 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for ZyVersa Therapeutics. GeoVax Labs' average media sentiment score of 0.49 beat ZyVersa Therapeutics' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Overall Sentiment
GeoVax Labs	Neutral
ZyVersa Therapeutics	Neutral

Summary

GeoVax Labs beats ZyVersa Therapeutics on 9 of the 13 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

Redhill Biopharma has higher revenue and earnings than ZyVersa Therapeutics. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	14.54	-$430K	$1.05 thousand	0.00
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

Redhill Biopharma has a beta of 4.98, indicating that its stock price is 398% more volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

In the previous week, Redhill Biopharma's average media sentiment score of 0.00 equaled ZyVersa Therapeutics'average media sentiment score.

Company	Overall Sentiment
Redhill Biopharma	Neutral
ZyVersa Therapeutics	Neutral

Redhill Biopharma's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Redhill Biopharma beats ZyVersa Therapeutics on 10 of the 10 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to TransCode Therapeutics?

ZyVersa Therapeutics (NASDAQ:ZVSA) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

In the previous week, TransCode Therapeutics had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 1 mentions for TransCode Therapeutics and 0 mentions for ZyVersa Therapeutics. ZyVersa Therapeutics' average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score.

Company	Overall Sentiment
ZyVersa Therapeutics	Neutral
TransCode Therapeutics	Neutral

ZyVersa Therapeutics' return on equity of -109.54% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZyVersa Therapeutics	N/A	-109.54%	-43.95%
TransCode Therapeutics	N/A	-875.35%	-50.36%

ZyVersa Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

ZyVersa Therapeutics beats TransCode Therapeutics on 6 of the 10 factors compared between the two stocks.

Get ZyVersa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZVSA vs. The Competition

Export

Metric	ZyVersa Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.13M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.17	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.04	8.66	10.96	6.46
Net Income	-$9.41M	$23.81M	$3.57B	$337.01M
7 Day Performance	-23.70%	3.39%	2.12%	1.69%
1 Month Performance	-28.70%	10.81%	5.25%	3.81%
1 Year Performance	-78.78%	62.61%	33.29%	23.90%

ZyVersa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZVSA ZyVersa Therapeutics	N/A	$0.14 flat	N/A	-78.8%	$1.13M	N/A	N/A	2	Gap Up High Trading Volume
DRMA Dermata Therapeutics	2.6185 of 5 stars	$1.17 -3.3%	$10.00 +754.7%	-79.9%	$4.87M	N/A	N/A	8	Positive News
ENVB Enveric Biosciences	0.5205 of 5 stars	$1.28 -2.3%	N/A	-90.4%	$4.82M	N/A	N/A	20	Short Interest Increase Gap Up
GOVX GeoVax Labs	2.6784 of 5 stars	$1.31 -5.1%	$150.00 +11,350.4%	-90.1%	$4.79M	$2.49M	N/A	10
RDHL Redhill Biopharma	1.3312 of 5 stars	$0.86 -5.4%	N/A	-59.7%	$4.72M	$290K	0.00	210	Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZVSA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ZyVersa Therapeutics (ZVSA) Competitors

ZVSA vs. DRMA, ENVB, GOVX, RDHL, and RNAZ

How does ZyVersa Therapeutics compare to Dermata Therapeutics?

Summary

How does ZyVersa Therapeutics compare to Enveric Biosciences?

Summary

How does ZyVersa Therapeutics compare to GeoVax Labs?

Summary

How does ZyVersa Therapeutics compare to Redhill Biopharma?

Summary

How does ZyVersa Therapeutics compare to TransCode Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVSA vs. The Competition

ZyVersa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ZyVersa Therapeutics (ZVSA) Competitors

ZVSA vs. DRMA, ENVB, GOVX, RDHL, and RNAZ

How does ZyVersa Therapeutics compare to Dermata Therapeutics?

Do institutionals and insiders hold more shares of DRMA or ZVSA?

Do analysts recommend DRMA or ZVSA?

Is DRMA or ZVSA more profitable?

Does the media refer more to DRMA or ZVSA?

Which has more risk & volatility, DRMA or ZVSA?

Which has preferable earnings & valuation, DRMA or ZVSA?

Summary

How does ZyVersa Therapeutics compare to Enveric Biosciences?

Which has more volatility & risk, ZVSA or ENVB?

Which has higher earnings and valuation, ZVSA or ENVB?

Do insiders and institutionals believe in ZVSA or ENVB?

Does the media favor ZVSA or ENVB?

Is ZVSA or ENVB more profitable?

Do analysts recommend ZVSA or ENVB?

Summary

How does ZyVersa Therapeutics compare to GeoVax Labs?

Is GOVX or ZVSA more profitable?

Do institutionals and insiders have more ownership in GOVX or ZVSA?

Which has more risk and volatility, GOVX or ZVSA?

Which has better valuation and earnings, GOVX or ZVSA?

Do analysts rate GOVX or ZVSA?

Does the media refer more to GOVX or ZVSA?

Summary

How does ZyVersa Therapeutics compare to Redhill Biopharma?

Which has higher earnings & valuation, RDHL or ZVSA?

Which has more volatility and risk, RDHL or ZVSA?

Does the media refer more to RDHL or ZVSA?

Is RDHL or ZVSA more profitable?

Do analysts rate RDHL or ZVSA?

Do institutionals & insiders have more ownership in RDHL or ZVSA?

Summary

How does ZyVersa Therapeutics compare to TransCode Therapeutics?

Does the media prefer ZVSA or RNAZ?

Is ZVSA or RNAZ more profitable?

Which has more volatility and risk, ZVSA or RNAZ?

Do insiders & institutionals have more ownership in ZVSA or RNAZ?

Which has stronger valuation and earnings, ZVSA or RNAZ?

Do analysts recommend ZVSA or RNAZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVSA vs. The Competition

ZyVersa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools